Praxis Precision Medicines, Inc. announced on October 16, 2025, that it has entered into an underwriting agreement to offer 3,025,480 shares of its common stock at $157.00 per share, aiming to raise approximately $567 million for research and development. The closing of the offering is expected on October 20, 2025.